transradial access, TRI, DRAGON trial, TCT 2015, non-inferiority, transfemoral access, TFO
Feature | Radial Access

Results from a prospective randomized trial of transradial (TRI) versus transfemoral (TFO) access in patients undergoing percutaneous coronary intervention found that TRI was non-inferior in terms of clinical effectiveness at one year and superior in reducing major bleeding complications at seven days compared to TFI.

Home October 18, 2015
Home
FFR-CT, cost and quality of life outcomes, TCT 2015, PLATFORM trial
Feature | CT Angiography (CTA)

New results from a multicenter, prospective study show that assessing fractional flow reserve estimated with computed tomography (FFR-CT) may reduce costs in selected symptomatic patients with suspected coronary artery disease (CAD).

Home October 18, 2015
Home
IN.PACT SFA study, TCT 2015, drug-coated balloons, PTA, SFA disease, superficial femoral artery
Feature | Peripheral Artery Disease (PAD)

Two-year results from the IN.PACT SFA study found the use of a drug-coated balloon was superior to conventional percutaneous transluminal angioplasty (PTA) in treating patients with superficial femoral artery (SFA) disease.

Home October 18, 2015
Home
News | Cardiac Imaging

The main pumping chamber of the heart ages differently in men and women, according to a new magnetic resonance imaging (MRI) study published online in the journal Radiology. Researchers said the findings may support different treatment approaches for men and women with heart disease.

Home October 16, 2015
Home
RESPECT trial, long-term study results, TCT 2015, PFO closure, recurrent cryptogenic stroke
Feature | Stroke

Long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent cryptogenic stroke in patients who had previously experienced one.

Home October 16, 2015
Home
News | Stents Bioresorbable

October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND ...

Home October 16, 2015
Home
Claret embolic protection, TAVR, cerebral protection
Feature | Heart Valve Technology

October 14, 2015 — Claret Medical, an innovator in cardiovascular cerebral protection, Data presented this week at ...

Home October 16, 2015
Home
ABSORB III trial, TCT 2015, bioresorbable vascular scaffold, BVS
Feature | Stents Bioresorbable

Results from a clinical trial showed that an everolimus-eluting bioresorbable vascular scaffold was non-inferior after one year compared to a current generation metallic drug-eluting stent (DES) in patients with coronary artery disease. Target lesion failure (TLF) was the primary endpoint for the study.

Home October 16, 2015
Home
News | Heart Valve Technology

Edwards Lifesciences Corp. announced that details on the 13 first-in-human compassionate use cases with its Forma transcatheter tricuspid repair system were presented at the 27th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. The results of the first seven cases were also published online this week in the Journal of the American College of Cardiology.

Home October 15, 2015
Home
News | Stents Bioresorbable

Two new advances in stent technology announced in recent days further reinforce the effectiveness of the next-generation bioabsorbable stents. Both new stents are designed to help reduce the risk of long-term complications for patients receiving a stent and will give interventional cardiologists more options in the care of cardiovascular patients.

Home October 15, 2015
Home
PARTNER II Trial, TCT 2015, Edwards Lifesciences, Sapien 3 valve, one-year results
Feature | Heart Valve Technology

One-year patient outcomes from the PARTNER II trial showed the low rate of 30-day complications with balloon-expandable transcatheter aortic valve replacement (TAVR) in high-risk and inoperable patients with aortic stenosis persisted with follow-up to one year.

Home October 15, 2015
Home
Technology | Heart Valve Technology

October 15, 2015 — U.S. Food and Drug Administration (FDA) has cleared Edwards Lifesciences Sapien XT transcatheter ...

Home October 15, 2015
Home
News | Stents Bioresorbable

Biotronik has announced results from the BIOSOLVE-II trial, investigating the safety and clinical performance of the world’s first clinically proven magnesium-based bioresorbable scaffold, at the Transcatheter Cardiovascular Therapeutics (TCT) 2015. The bioresorbable scaffold met its primary angiographic endpoint and demonstrated an outstanding safety profile. The announcement of clinical data from BIOSOLVE-II will be accompanied by publication in The Lancet.

Home October 15, 2015
Home
News | Drug-Eluting Balloons

C. R. Bard Inc. announced the presentation of the 12-month results from the Lutonix Global Real-World Registry at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 meeting. These results come just months after publication in the New England Journal of Medicine of the one-year data from the Lutonix 035 drug coated balloon (DCB) catheter pivotal, randomized LEVANT 2 trial.

Home October 15, 2015
Home
News | Stents Bifurcation

Tryton Medical Inc. announced results from the pivotal Tryton Confirmatory Study confirming the acceptable acute safety profile of the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions in vessels appropriate for a ≥2.5mm stent. Results were presented as part of the Featured Clinical Research session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF) being held in San Francisco, California.

Home October 14, 2015
Home
Subscribe Now